持田製薬 announced that it has started a domestic Phase 3 (P3) clinical trial of BON-001, a candidate treatment for morning sickness in pregnant women. The development code is BON-001, and the generic name is doxylamine succinate/pyridoxine hydrochloride.
持田製薬 has started a domestic Phase 3 clinical trial of BON-001, a candidate treatment for morning sickness. The study will evaluate its efficacy and safety in treating nausea and vomiting associated with pregnancy.
BON-001 is the development code, and its generic name is a combination of doxylamine succinate and pyridoxine hydrochloride. The domestic Phase 3 trial is reportedly planned as a large-scale, multicenter study.